Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

V.H. van der Velden; A. van der Sluijs-Geling; B.E. Gibson; J.G. te Marvelde; P.G. Hoogeveen; W.C. Hop; K. Wheatley; M.B. Bierings; G.J. Schuurhuis; S.S. de Graaf; E.R. van Wering; J.J. van Dongen

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

Translated title of the contribution: Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

V.H. van der Velden
, A. van der Sluijs-Geling
, B.E. Gibson
, J.G. te Marvelde
, P.G. Hoogeveen
, W.C. Hop
, K. Wheatley
, M.B. Bierings
, G.J. Schuurhuis
, S.S. de Graaf
, E.R. van Wering
, J.J. van Dongen

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol
Original language	Undefined/Unknown
Pages (from-to)	1599-1606
Number of pages	8
Journal	Leukemia
Volume	24
Issue number	9
Publication status	Published - 2010

Cite this

van der Velden, V. H., van der Sluijs-Geling, A., Gibson, B. E., te Marvelde, J. G., Hoogeveen, P. G., Hop, W. C., Wheatley, K., Bierings, M. B., Schuurhuis, G. J., de Graaf, S. S., van Wering, E. R., & van Dongen, J. J. (2010). Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24(9), 1599-1606.

@article{02319fc6d61244a696091df580f54e94,

title = "Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol",

author = "\{van der Velden\}, V.H. and \{van der Sluijs-Geling\}, A. and B.E. Gibson and \{te Marvelde\}, J.G. and P.G. Hoogeveen and W.C. Hop and K. Wheatley and M.B. Bierings and G.J. Schuurhuis and \{de Graaf\}, S.S. and \{van Wering\}, E.R. and \{van Dongen\}, J.J.",

year = "2010",

language = "Undefined/Unknown",

volume = "24",

pages = "1599--1606",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "9",

}

van der Velden, VH, van der Sluijs-Geling, A, Gibson, BE, te Marvelde, JG, Hoogeveen, PG, Hop, WC, Wheatley, K, Bierings, MB, Schuurhuis, GJ, de Graaf, SS, van Wering, ER & van Dongen, JJ 2010, 'Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol', Leukemia, vol. 24, no. 9, pp. 1599-1606.

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. / van der Velden, V.H.; van der Sluijs-Geling, A.; Gibson, B.E. et al.
In: Leukemia, Vol. 24, No. 9, 2010, p. 1599-1606.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

AU - van der Velden, V.H.

AU - van der Sluijs-Geling, A.

AU - Gibson, B.E.

AU - te Marvelde, J.G.

AU - Hoogeveen, P.G.

AU - Hop, W.C.

AU - Wheatley, K.

AU - Bierings, M.B.

AU - Schuurhuis, G.J.

AU - de Graaf, S.S.

AU - van Wering, E.R.

AU - van Dongen, J.J.

PY - 2010

Y1 - 2010

M3 - Article

SN - 0887-6924

VL - 24

SP - 1599

EP - 1606

JO - Leukemia

JF - Leukemia

IS - 9

ER -